Stay tuned for the market movements in the S&P500 index on Tuesday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
Dialysis provider DaVita Inc. (NYSE:DVA) announced better-than-expected revenue in Q1 CY2025, with sales up 5% year on year to $3.22 billion. Its non-GAAP profit of $2 per share was 1% below analysts’ consensus estimates.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 13.3%. This drawdown was worse than the S&P 500’s 5.8% fall.
Large-cap stocks had poor performance last week, including UnitedHealth Group, Global Payments, Applovin, Humana, DaVita, Meta Platforms, Yum China, CoreWeave, Burlington Stores, Super Micro Computer, and GlobalFoundries.
Wall Street pared early morning gains by midday Monday, as investor caution returned despite a temporary easing in U.S.-China trade tensions. While the initial market reaction was positive, especially in tech, enthusiasm faded as the trading session progressed.
Stay tuned for the market movements in the S&P500 index on Monday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
Let’s dig into the relative performance of DaVita (NYSE:DVA) and its peers as we unravel the now-completed Q4 outpatient & specialty care earnings season.
